deltatrials
Unknown NA NCT02109913

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole

Sponsor: Amsterdam UMC, location VUmc

Updated 10 times since 2017 Last updated: Oct 11, 2019 Started: Mar 31, 2014 Primary completion: Jan 31, 2021 Completion: Jan 31, 2021

A NA clinical study on Hormone Receptor Positive Malignant Neoplasm of Breast and Metastatic Breast Cancer, this trial is ongoing. The trial is conducted by Amsterdam UMC, location VUmc and has accumulated 10 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

10 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown NA

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown NA

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown NA

    Status: Unknown StatusUnknown

  4. May 2022 — Jul 2024 [monthly]

    Unknown Status NA

  5. Nov 2021 — May 2022 [monthly]

    Unknown Status NA

    Status: Active Not RecruitingUnknown Status

Show 5 earlier versions
  1. Jan 2021 — Nov 2021 [monthly]

    Active Not Recruiting NA

  2. Nov 2019 — Jan 2021 [monthly]

    Active Not Recruiting NA

  3. Jun 2018 — Nov 2019 [monthly]

    Active Not Recruiting NA

  4. Apr 2017 — Jun 2018 [monthly]

    Active Not Recruiting NA

    Status: RecruitingActive Not Recruiting

  5. Jan 2017 — Apr 2017 [monthly]

    Recruiting NA

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amsterdam UMC, location VUmc
  • Borstkanker Onderzoek Groep
  • Novartis
Data source: Amsterdam UMC, location VUmc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Almere Stad, Netherlands, Amsterdam, Netherlands, Apeldoorn, Netherlands, Arnhem, Netherlands, Breda, Netherlands, Delft, Netherlands, Den Helder, Netherlands, Deventer, Netherlands, Eindhoven, Netherlands, Gouda, Netherlands and 14 more location s